Issue 101

Natural Medicine Health Act

Colorado’s Natural Medicine Health Act

On 8 November, the Colorado electorate will vote on the Natural Medicine Health Act, Proposition 122, to decriminalise entheogens and lay the groundwork for the regulation of psychedelic compounds.

The Natural Medicine Health Act requires rules to be written for a psilocybin programme by 2024, with service centres expected to open in 2025. This would create the second state-wide industry in the US, after Oregon, and one that could quickly become the biggest.

Similar to Oregon’s programme, adults over 21 in Colorado could access psilocybin services without a diagnosis, prescription or referral. This presents an addressable market of over 3 million, 24% larger than that in Oregon.

READ MORE

THE UK'S PSYCHEDELIC HEALTHCARE ECOSYSTEM

Innovation in psychedelic healthcare is advancing quickly in the UK, with industry-leading companies based in the country.

Read More

THE ECONOMIST EXPLORES PSYCHEDELIC MEDICINE

As research into psychedelic compounds proliferates, The Economist reviews the current studies and treatment efficacy.

Read More

BUSINESS AND INVESTMENT

Silo Pharma closes US$5.75m public offering.

Beckley Retreats closes US$1.5m seed funding round.

Healing Maps raises US$1m in seed funding round.

PharmaTher releases 2022 financial results.

Silo Wellness to acquire Dyscovry Science.

Psyence exports psilocybe cubensis to Portugal.

Standards of psilocybin-assisted therapy.

Ketamine provides hope for severely depressed.

Ketamine telehealth and the public health emergency deadline.

The benefits and limitations of psychedelic healthcare.

The Psychedelics as Medicine Report positions organisations in front of regulators, researchers and investors.

With over 60,000 downloads, the industry-leading publication contains proprietary market data and insights to identify emerging opportunities.

Previous partners include COMPASS Pathways, Cybin and Filament Health.

To be included in the fourth edition and to discuss future events, please contact grace@psych.global

CONTACT FORM

SCIENCE AND RESEARCH

Scientists discover antidepressant non-hallucinogenic LSD analogues.

LSD and psilocybin’s impact on the brain’s control energy landscape.

Psychedelic medicines without the hallucinations.

The efficacy of microdosing called into question.

The mechanisms of action of psychedelic medicine.

REGULATION AND LEGISLATION

DEA says Right-to-Try activists have commercial interests.

Colorado activists divided on decriminalisation measure.

Psilocybin regulation in Canada.

Alberta updates policy for non-hospital ketamine infusions.

ARTICLES OF INTEREST

Record use of antidepressants in UK adolescents.

The value of bad psychedelic experiences.

Partner with us